{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:07:11Z","timestamp":1772806031860,"version":"3.50.1"},"reference-count":287,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Ever since it was first reported in Wuhan, China, the coronavirus-induced disease of 2019 (COVID-19) has become an enigma of sorts with ever expanding reports of direct and indirect effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on almost all the vital organ systems. Along with inciting acute pulmonary complications, the virus attacks the cardiac, renal, hepatic, and gastrointestinal systems as well as the central nervous system (CNS). The person-to-person variability in susceptibility of individuals to disease severity still remains a puzzle, although the comorbidities and the age\/gender of a person are believed to play a key role. SARS-CoV-2 needs angiotensin-converting enzyme 2 (ACE2) receptor for its infectivity, and the association between SARS-CoV-2 and ACE2 leads to a decline in ACE2 activity and its neuroprotective effects. Acute respiratory distress may also induce hypoxia, leading to increased oxidative stress and neurodegeneration. Infection of the neurons along with peripheral leukocytes\u2019 activation results in proinflammatory cytokine release, rendering the brain more susceptible to neurodegenerative changes. Due to the advancement in molecular biology techniques and vaccine development programs, the world now has hope to relatively quickly study and combat the deadly virus. On the other side, however, the virus seems to be still evolving with new variants being discovered periodically. In keeping up with the pace of this virus, there has been an avalanche of studies. This review provides an update on the recent progress in adjudicating the CNS-related mechanisms of SARS-CoV-2 infection and its potential to incite or accelerate neurodegeneration in surviving patients. Current as well as emerging therapeutic opportunities and biomarker development are highlighted.<\/jats:p>","DOI":"10.3390\/brainsci12020190","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T01:46:08Z","timestamp":1643593568000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Peek into Pandora\u2019s Box: COVID-19 and Neurodegeneration"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-4243","authenticated-orcid":false,"given":"Abhishek","family":"Chandra","sequence":"first","affiliation":[{"name":"Independent Researcher, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-8583","authenticated-orcid":false,"given":"Ashu","family":"Johri","sequence":"additional","affiliation":[{"name":"Independent Researcher, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102779","DOI":"10.1016\/j.jaut.2021.102779","article-title":"Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies","volume":"126","author":"Kannan","year":"2022","journal-title":"J. Autoimmun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"ref_3","unstructured":"Aleem, A., Akbar Samad, A.B., and Slenker, A.K. (2022). Emerging Variants of SARS-CoV-2 and Novel Therapeutics against Coronavirus (COVID-19), StatPearls."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/tmi.13383","article-title":"The COVID-19 epidemic","volume":"25","author":"Velavan","year":"2020","journal-title":"Trop. Med. Int. Health"},{"key":"ref_6","first-page":"157","article-title":"WHO Declares COVID-19 a Pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cytogfr.2020.11.001","article-title":"SARS-CoV-2: Targeted managements and vaccine development","volume":"58","author":"Bakhiet","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12931-020-01479-w","article-title":"From SARS and MERS to COVID-19: A brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses","volume":"21","author":"Zhu","year":"2020","journal-title":"Respir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"FSO605","DOI":"10.2144\/fsoa-2020-0091","article-title":"Toll-like receptors and COVID-19: A two-faced story with an exciting ending","volume":"6","author":"Onofrio","year":"2020","journal-title":"Future Sci. OA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_12","first-page":"2","article-title":"Neuropathology of COVID-19 (neuro-COVID): Clinicopathological update","volume":"2","author":"Lou","year":"2021","journal-title":"Free Neuropathol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sun, B., Tang, N., Peluso, M.J., Iyer, N.S., Torres, L., Donatelli, J.L., Munter, S.E., Nixon, C.C., Rutishauser, R.L., and Rodriguez-Barraquer, I. (2021). Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. Cells, 10.","DOI":"10.3390\/cells10020386"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12035-020-02134-7","article-title":"Neurological Complications Associated with the Blood-Brain Barrier Damage Induced by the Inflammatory Response during SARS-CoV-2 Infection","volume":"58","author":"Aguilera","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cell.2020.08.028","article-title":"Effects of COVID-19 on the Nervous System","volume":"183","author":"Iadecola","year":"2020","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMc2033369","article-title":"Microvascular Injury in the Brains of Patients with Covid-19","volume":"384","author":"Lee","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117308","DOI":"10.1016\/j.jns.2021.117308","article-title":"Susceptibility-weighted imaging reveals cerebral microvascular injury in severe COVID-19","volume":"421","author":"Conklin","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/acn3.51350","article-title":"Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 \u201clong haulers\u201d","volume":"8","author":"Graham","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Doyle, M.F. (2021). Central nervous system outcomes of COVID-19. Transl. Res.","DOI":"10.1016\/j.trsl.2021.09.002"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2215-0366(21)00084-5","article-title":"6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s00415-021-10406-y","article-title":"Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)","volume":"268","author":"Harapan","year":"2021","journal-title":"J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/cjn.2020.173","article-title":"Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic","volume":"48","author":"Roy","year":"2021","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e213071","DOI":"10.1001\/jamanetworkopen.2021.3071","article-title":"Comparison of Time to Clinical Improvement with vs without Remdesivir Treatment in Hospitalized Patients with COVID-19","volume":"4","author":"Garibaldi","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mozaffari, E., Chandak, A., Zhang, Z., Liang, S., Thrun, M., Gottlieb, R.L., Kuritzkes, D.R., Sax, P.E., Wohl, D.A., and Casciano, R. (2021). Remdesivir Treatment in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. Clin. Infect. Dis., ciab875.","DOI":"10.1093\/cid\/ciab875"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.7326\/M21-0653","article-title":"Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19: A Randomized Trial","volume":"174","author":"Olsen","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"105631","DOI":"10.1016\/j.ejps.2020.105631","article-title":"Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial","volume":"157","author":"Lou","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"683296","DOI":"10.3389\/fphar.2021.683296","article-title":"Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jiac.2021.10.011","article-title":"Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study","volume":"28","author":"Morikawa","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijid.2021.12.324","article-title":"Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients","volume":"115","author":"Koseki","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2116\/analsci.21N004","article-title":"Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19","volume":"37","author":"Moriiwa","year":"2021","journal-title":"Anal. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1620\/tjem.251.87","article-title":"Uric Acid Elevation by Favipiravir, an Antiviral Drug","volume":"251","author":"Mishima","year":"2020","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1186\/s13063-020-04825-x","article-title":"A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Bosaeed","year":"2020","journal-title":"Trials"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.2147\/IJGM.S329881","article-title":"Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study","volume":"14","author":"Alotaibi","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_36","first-page":"CD013587","article-title":"Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"106239","DOI":"10.1016\/j.ijantimicag.2020.106239","article-title":"Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes","volume":"57","author":"Gautret","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"106240","DOI":"10.1016\/j.ijantimicag.2020.106240","article-title":"Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis","volume":"57","author":"Million","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/mdr.2020.0232","article-title":"Combination of Hydroxychloroquine Plus Azithromycin as Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity","volume":"27","author":"Hache","year":"2021","journal-title":"Microb. Drug Resist."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"107732","DOI":"10.1016\/j.intimp.2021.107732","article-title":"Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis","volume":"96","author":"Xiang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ijid.2021.01.009","article-title":"Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching","volume":"105","author":"Huang","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13223-021-00609-3","article-title":"Potential therapeutic approach of intravenous immunoglobulin against COVID-19","volume":"17","author":"Kolahchi","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/jmv.26727","article-title":"Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence","volume":"93","author":"Moradimajd","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMe2035678","article-title":"(A Little) Clarity on Convalescent Plasma for Covid-19","volume":"384","author":"Katz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults","volume":"384","author":"Libster","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fodor, E., Muller, V., Ivanyi, Z., Berki, T., Kuten Pella, O., Hornyak, I., Ambrus, M., Sarkany, A., Skazel, A., and Madar, A. (2021). Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection. Infect. Dis. Ther.","DOI":"10.1007\/s40121-022-00637-5"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13063-021-05116-9","article-title":"Effect of dexamethasone in patients with ARDS and COVID-19\u2014Prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial","volume":"22","author":"Malaska","year":"2021","journal-title":"Trials"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ranjbar, K., Moghadami, M., Mirahmadizadeh, A., Fallahi, M.J., Khaloo, V., Shahriarirad, R., Erfani, A., Khodamoradi, Z., and Gholampoor Saadi, M.H. (2021). Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06045-3"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","article-title":"Methylprednisolone as Adjunctive Therapy for Patients Hospitalized with Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial","volume":"72","author":"Jeronimo","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Pinzon, M.A., Ortiz, S., Holguin, H., Betancur, J.F., Cardona Arango, D., Laniado, H., Arias Arias, C., Munoz, B., Quiceno, J., and Jaramillo, D. (2021). Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252057"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"174579","DOI":"10.1016\/j.ejphar.2021.174579","article-title":"Use of steroids in COVID-19 patients: A meta-analysis","volume":"914","author":"Thakur","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2021.01.016","article-title":"Anakinra for patients with COVID-19: A meta-analysis of non-randomized cohort studies","volume":"86","author":"Pasin","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jaci.2020.11.006","article-title":"Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study","volume":"147","author":"Bozzi","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2021.01.024","article-title":"Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia","volume":"147","author":"Pontali","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3947\/ic.2020.0126","article-title":"Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis","volume":"53","author":"Quiros","year":"2021","journal-title":"Infect. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41375-021-01214-4","article-title":"Ruxolitinib withdrawal due to the COVID-19","volume":"35","author":"Lucijanic","year":"2021","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.31053\/1853.0605.v78.n3.32800","article-title":"Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome","volume":"78","author":"Iastrebner","year":"2021","journal-title":"Rev. Fac. Cien. Med. Univ. Nac. Cordoba"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13063-021-05072-4","article-title":"A Phase I\/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial","volume":"22","author":"Mussetti","year":"2021","journal-title":"Trials"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"749657","DOI":"10.3389\/fmed.2021.749657","article-title":"Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19","volume":"8","author":"Masia","year":"2021","journal-title":"Front. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: An observational cohort study","volume":"60","year":"2021","journal-title":"Rheumatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/cts.12971","article-title":"Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation","volume":"14","author":"Mortara","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19","volume":"40","author":"Razonable","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"105026","DOI":"10.1016\/j.jcv.2021.105026","article-title":"Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge","volume":"145","author":"Bierle","year":"2021","journal-title":"J. Clin. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s40121-021-00525-4","article-title":"Efficacy of Bamlanivimab\/Etesevimab and Casirivimab\/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern","volume":"10","author":"Falcone","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","article-title":"Tocilizumab for Treatment of Mechanically Ventilated Patients with COVID-19","volume":"73","author":"Somers","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/18761038MTA55OTgh5","article-title":"Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review","volume":"16","author":"Kulanthaivel","year":"2021","journal-title":"Rev. Recent Clin. Trials"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.transproceed.2020.06.003","article-title":"Successful Treatment of Severe COVID-19 Pneumonia with Clazakizumab in a Heart Transplant Recipient: A Case Report","volume":"52","author":"Vaidya","year":"2020","journal-title":"Transplant. Proc."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"549","DOI":"10.31083\/j.rcm2203065","article-title":"Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19","volume":"22","author":"Buryachkovskaya","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ejhpharm-2020-002322","article-title":"Involvement of interleukin 6 in SARS-CoV-2 infection: Siltuximab as a therapeutic option against COVID-19","volume":"27","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-021-01299-x","article-title":"Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19","volume":"35","author":"Gritti","year":"2021","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"MAbs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00011-021-01507-5","article-title":"The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: Results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study","volume":"70","author":"Lomakin","year":"2021","journal-title":"Inflamm. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14712598.2021.1847269","article-title":"A comprehensive review on sarilumab in COVID-19","volume":"21","author":"Khiali","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"21775","DOI":"10.1038\/s41598-020-78492-y","article-title":"Blockage of interleukin-1beta with canakinumab in patients with Covid-19","volume":"10","author":"Landi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijid.2020.12.073","article-title":"Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study","volume":"104","author":"Generali","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1111\/jdv.16590","article-title":"Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient","volume":"34","author":"Benhadou","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1111\/jdv.17003","article-title":"A multicenter study on effectiveness and safety of risankizumab in psoriasis: An Italian 16-week real-life experience during the COVID-19 pandemic","volume":"35","author":"Hansel","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1136\/annrheumdis-2020-218029","article-title":"Correspondence on \u2018Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab\u2019","volume":"80","author":"Messina","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1186\/s13063-020-04925-8","article-title":"Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial","volume":"21","author":"Liu","year":"2020","journal-title":"Trials"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/bcp.14437","article-title":"Potential role of IL-17 blocking agents in the treatment of severe COVID-19?","volume":"87","author":"Bulat","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.2147\/JIR.S329252","article-title":"Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19","volume":"14","author":"Zou","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijp.IJP_615_20","article-title":"Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors","volume":"53","author":"Cure","year":"2021","journal-title":"Indian J. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1017\/cts.2021.805","article-title":"Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFalpha-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure","volume":"5","author":"Hachem","year":"2021","journal-title":"J. Clin. Transl. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Fakharian, A., Barati, S., Mohamadi, M., and Dastan, F. (2021). Successful Management of COVID-19 with Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient. J. Cardiothorac. Vasc. Anesth.","DOI":"10.1053\/j.jvca.2020.12.023"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.mayocp.2020.08.038","article-title":"GM-CSF Neutralization with Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study","volume":"95","author":"Temesgen","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_93","unstructured":"Temesgen, Z., Burger, C.D., Baker, J., Polk, C., Libertin, C.R., Kelley, C.F., Marconi, V.C., Orenstein, R., Catterson, V.M., and Aronstein, W.S. (2021). Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): A phase 3, randomised, placebo-controlled trial. Lancet Respir. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41577-020-0357-7","article-title":"GM-CSF-based treatments in COVID-19: Reconciling opposing therapeutic approaches","volume":"20","author":"Lang","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3389\/fimmu.2020.01625","article-title":"Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies","volume":"11","author":"Bonaventura","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Fisher, B.A., Veenith, T., Slade, D., Gaskell, C., Rowland, M., Whitehouse, T., Scriven, J., Parekh, D., Balasubramaniam, M.S., and Cooke, G. (2021). Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): A randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir. Med.","DOI":"10.1016\/S2213-2600(21)00460-4"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2665-9913(20)30170-3","article-title":"GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: A single-centre, prospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2665-9913(21)00070-9","article-title":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): An investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial","volume":"3","author":"Cremer","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_99","first-page":"9169","article-title":"SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?","volume":"24","author":"Quagliariello","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e14623","DOI":"10.1111\/dth.14623","article-title":"Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center","volume":"34","author":"Onsun","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1136\/annrheumdis-2020-218171","article-title":"COVID-19 in patients with rheumatological diseases treated with anti-TNF","volume":"80","author":"Brito","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1007\/s11033-020-05830-8","article-title":"Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147)","volume":"47","author":"Sehirli","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"111546","DOI":"10.1016\/j.jinorgbio.2021.111546","article-title":"Melatonin interferes with COVID-19 at several distinct ROS-related steps","volume":"223","author":"Camp","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eprac.2021.06.001","article-title":"Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy","volume":"27","author":"Cross","year":"2021","journal-title":"Endocr. Pract."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1056\/NEJMc2011400","article-title":"Multiorgan and Renal Tropism of SARS-CoV-2","volume":"383","author":"Puelles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1474-4422(20)30308-2","article-title":"Neuropathology of patients with COVID-19 in Germany: A post-mortem case series","volume":"19","author":"Matschke","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","article-title":"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study","volume":"1","author":"Chu","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41422-020-0390-x","article-title":"SARS-CoV-2 infects human neural progenitor cells and brain organoids","volume":"30","author":"Zhang","year":"2020","journal-title":"Cell Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.stem.2019.08.002","article-title":"Complex Oscillatory Waves Emerging from Cortical Organoids Model Early Human Brain Network Development","volume":"25","author":"Trujillo","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1212\/NXI.0000000000000893","article-title":"Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients","volume":"7","author":"Alexopoulos","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.stem.2020.09.016","article-title":"Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium","volume":"27","author":"Jacob","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.stemcr.2021.01.016","article-title":"SARS-CoV-2 targets glial cells in human cortical organoids","volume":"16","author":"McMahon","year":"2021","journal-title":"Stem Cell Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2020.10.001","article-title":"SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids","volume":"27","author":"Pellegrini","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jmv.25915","article-title":"Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)","volume":"92","author":"Bryce","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Trypsteen, W., Van Cleemput, J., Snippenberg, W.V., Gerlo, S., and Vandekerckhove, L. (2020). On the whereabouts of SARS-CoV-2 in the human body: A systematic review. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1009037"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e20202135","DOI":"10.1084\/jem.20202135","article-title":"Neuroinvasion of SARS-CoV-2 in human and mouse brain","volume":"218","author":"Song","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMc2019373","article-title":"Neuropathological Features of Covid-19","volume":"383","author":"Solomon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","article-title":"Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19","volume":"24","author":"Meinhardt","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Ojha","year":"2020","journal-title":"Science"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e0027021","DOI":"10.1128\/mSphere.00270-21","article-title":"Replication Kinetics, Cell Tropism, and Associated Immune Responses in SARS-CoV-2- and H5N1 Virus-Infected Human Induced Pluripotent Stem Cell-Derived Neural Models","volume":"6","author":"Bauer","year":"2021","journal-title":"mSphere"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"102436","DOI":"10.1016\/j.scr.2021.102436","article-title":"Non-permissive SARS-CoV-2 infection in human neurospheres","volume":"54","author":"Pedrosa","year":"2021","journal-title":"Stem Cell Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41593-020-00771-8","article-title":"The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice","volume":"24","author":"Rhea","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1128\/JVI.00737-08","article-title":"Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2","volume":"82","author":"Netland","year":"2008","journal-title":"J. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/jmv.25728","article-title":"The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamaneurol.2020.2065","article-title":"Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review","volume":"77","author":"Zubair","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bbi.2020.03.031","article-title":"Nervous system involvement after infection with COVID-19 and other coronaviruses","volume":"87","author":"Wu","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Erickson, M.A., Rhea, E.M., Knopp, R.C., and Banks, W.A. (2021). Interactions of SARS-CoV-2 with the Blood-Brain Barrier. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052681"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11906-014-0512-2","article-title":"Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke","volume":"17","author":"Bennion","year":"2015","journal-title":"Curr. Hypertens Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-5793(02)03640-2","article-title":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme","volume":"532","author":"Harmer","year":"2002","journal-title":"FEBS Lett."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"R373","DOI":"10.1152\/ajpregu.00292.2006","article-title":"Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system","volume":"292","author":"Doobay","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1471-4159.2008.05723.x","article-title":"Angiotensin-converting enzyme 2 in the brain: Properties and future directions","volume":"107","author":"Xia","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1113\/expphysiol.2007.041657","article-title":"RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2","volume":"93","author":"Lin","year":"2008","journal-title":"Exp. Physiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s11064-018-2679-4","article-title":"ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models","volume":"44","author":"Alenina","year":"2019","journal-title":"Neurochem. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect. Dis. Poverty"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"113837","DOI":"10.1016\/j.expneurol.2021.113837","article-title":"ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations","volume":"345","author":"Hernandez","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e59136","DOI":"10.7554\/eLife.59136","article-title":"Neuropathogenesis of SARS-CoV-2 infection","volume":"9","author":"Khan","year":"2020","journal-title":"Elife"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","article-title":"Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms","volume":"11","author":"Baig","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1021\/acschemneuro.0c00174","article-title":"Letter to the Editor Regarding the Viewpoint \u201cEvidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanism\u201d","volume":"11","author":"Toljan","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e03185-20","DOI":"10.1128\/mBio.03185-20","article-title":"Recombinant ACE2 Expression Is Required for SARS-CoV-2 to Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses","volume":"11","author":"Schutt","year":"2020","journal-title":"mBio"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1042\/CS20200483","article-title":"Brain angiotensin converting enzyme-2 in central cardiovascular regulation","volume":"134","author":"Mohammed","year":"2020","journal-title":"Clin. Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbrc.2020.09.042","article-title":"The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues","volume":"533","author":"Qiao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s41061-021-00353-7","article-title":"The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19","volume":"379","author":"Ahmad","year":"2021","journal-title":"Top. Curr. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"Kuster","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/HYPERTENSIONAHA.120.15291","article-title":"ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use during the Pandemic: The Pediatric Perspective","volume":"76","author":"South","year":"2020","journal-title":"Hypertension"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/acn3.51348","article-title":"Brain dysfunction in COVID-19 and CAR-T therapy: Cytokine storm-associated encephalopathy","volume":"8","author":"Pensato","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"155404","DOI":"10.1016\/j.cyto.2020.155404","article-title":"Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations","volume":"138","author":"Thepmankorn","year":"2021","journal-title":"Cytokine"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.16659","article-title":"Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients","volume":"189","author":"Wan","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/svn-2020-000431","article-title":"Acute cerebrovascular disease following COVID-19: A single center, retrospective, observational study","volume":"5","author":"Li","year":"2020","journal-title":"Stroke Vasc. Neurol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1002\/ajh.25822","article-title":"Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability","volume":"95","author":"Tan","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cns.13569","article-title":"Peripheral inflammation and blood-brain barrier disruption: Effects and mechanisms","volume":"27","author":"Huang","year":"2021","journal-title":"CNS Neurosci. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/pr.117.014647","article-title":"Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions","volume":"70","author":"Erickson","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41392-021-00719-9","article-title":"SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Hugon, J. (2021). Long-Covid: Cognitive Deficits (Brain Fog) and Brain Lesions in Non-Hospitalized Patients. Presse Med., 104090.","DOI":"10.1016\/j.lpm.2021.104090"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/YCO.0000000000000688","article-title":"Coronavirus disease 2019 and neurodegenerative disease: What will the future bring?","volume":"34","author":"McAlpine","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"664965","DOI":"10.3389\/fnagi.2021.664965","article-title":"Impact of COVID-19 Pandemic on Patients with Neurodegenerative Diseases","volume":"13","author":"Hu","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"698169","DOI":"10.3389\/fmicb.2021.698169","article-title":"Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms","volume":"12","author":"Proal","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/brain\/awab148","article-title":"COVID-19 neuropathology at Columbia University Irving Medical Center\/New York Presbyterian Hospital","volume":"144","author":"Thakur","year":"2021","journal-title":"Brain"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13195-020-00640-3","article-title":"Immediate and long-term consequences of COVID-19 infections for the development of neurological disease","volume":"12","author":"Heneka","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"fcaa069","DOI":"10.1093\/braincomms\/fcaa069","article-title":"The cognitive consequences of the COVID-19 epidemic: Collateral damage?","volume":"2","author":"Ritchie","year":"2020","journal-title":"Brain Commun."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1080\/13854046.2020.1811894","article-title":"Post-traumatic stress disorder: A differential diagnostic consideration for COVID-19 survivors","volume":"34","author":"Kaseda","year":"2020","journal-title":"Clin. Neuropsychol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03710-0","article-title":"Dysregulation of brain and choroid plexus cell types in severe COVID-19","volume":"595","author":"Yang","year":"2021","journal-title":"Nature"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e101064","DOI":"10.15252\/embj.2018101064","article-title":"Systemic inflammation impairs microglial Abeta clearance through NLRP3 inflammasome","volume":"38","author":"Tejera","year":"2019","journal-title":"EMBO J."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","article-title":"NLRP3 inflammasome activation drives tau pathology","volume":"575","author":"Ising","year":"2019","journal-title":"Nature"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12035-021-02593-6","article-title":"SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia","volume":"59","author":"Olajide","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e106230","DOI":"10.15252\/embj.2020106230","article-title":"SARS-CoV-2 targets neurons of 3D human brain organoids","volume":"39","author":"Ramani","year":"2020","journal-title":"EMBO J."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-021-00850-3","article-title":"Network medicine links SARS-CoV-2\/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment","volume":"13","author":"Zhou","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/mds.28118","article-title":"Can the 2019 Novel Coronavirus Cause Parkinson\u2019s Disease?","volume":"35","author":"Achbani","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-202073","article-title":"COVID-19 and Parkinson\u2019s Disease: Are We Dealing with Short-term Impacts or Something Worse?","volume":"10","author":"Victorino","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3233\/JPD-202038","article-title":"The Impact of the COVID-19 Pandemic on Parkinson\u2019s Disease: Hidden Sorrows and Emerging Opportunities","volume":"10","author":"Helmich","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"106349","DOI":"10.1016\/j.clineuro.2020.106349","article-title":"Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review","volume":"200","author":"Kubota","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s10072-020-04593-1","article-title":"Functional movement disorders in a patient with COVID-19","volume":"41","author":"Piscitelli","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5334\/tohm.595","article-title":"New-Onset Movement Disorders Associated with COVID-19","volume":"11","author":"Brandao","year":"2021","journal-title":"Tremor. Other Hyperkinet. Mov."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Garg, A., Goyal, S., and Comellas, A.P. (2021). Post-acute COVID-19 functional movement disorder. SAGE Open Med. Case Rep., 9.","DOI":"10.1177\/2050313X211039377"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"670298","DOI":"10.3389\/fncel.2021.670298","article-title":"Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons from Viral RNA Neurotropism and Possible Relevance to Parkinson\u2019s Disease","volume":"15","author":"Awogbindin","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e2130645","DOI":"10.1001\/jamanetworkopen.2021.30645","article-title":"Assessment of Cognitive Function in Patients After COVID-19 Infection","volume":"4","author":"Becker","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc2008597","article-title":"Neurologic Features in Severe SARS-CoV-2 Infection","volume":"382","author":"Helms","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Bartoszek, A., Walkowiak, D., Bartoszek, A., and Kardas, G. (2020). Mental Well-Being (Depression, Loneliness, Insomnia, Daily Life Fatigue) during COVID-19 Related Home-Confinement-A Study from Poland. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17207417"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Rodriguez-Fernandez, P., Gonzalez-Santos, J., Santamaria-Pelaez, M., Soto-Camara, R., Sanchez-Gonzalez, E., and Gonzalez-Bernal, J.J. (2021). Psychological Effects of Home Confinement and Social Distancing Derived from COVID-19 in the General Population-A Systematic Review. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18126528"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1017\/S0033291721000933","article-title":"Investigating the effect of national government physical distancing measures on depression and anxiety during the COVID-19 pandemic through meta-analysis and meta-regression","volume":"51","author":"Marziali","year":"2021","journal-title":"Psychol. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"112954","DOI":"10.1016\/j.psychres.2020.112954","article-title":"Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: A web-based cross-sectional survey","volume":"288","author":"Huang","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JAD-200604","article-title":"The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer\u2019s Disease during the COVID-19 Crisis","volume":"76","author":"Gillet","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s13760-021-01732-z","article-title":"Lockdown effects on Parkinson\u2019s disease during COVID-19 pandemic: A pilot study","volume":"121","author":"Falla","year":"2021","journal-title":"Acta Neurol. Belg."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.parkreldis.2021.07.013","article-title":"A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson\u2019s disease. The ERCOPARK study","volume":"89","author":"Fabbri","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14737175.2021.1923480","article-title":"The impact of COVID-19 on palliative care for people with Parkinson\u2019s and response to future pandemics","volume":"21","author":"Chaudhuri","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Luis-Martinez, R., Di Marco, R., Weis, L., Cianci, V., Pistonesi, F., Baba, A., Carecchio, M., Biundo, R., Tedesco, C., and Masiero, S. (2021). Impact of social and mobility restrictions in Parkinson\u2019s disease during COVID-19 lockdown. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02364-9"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Forte, G., Favieri, F., Tambelli, R., and Casagrande, M. (2020). COVID-19 Pandemic in the Italian Population: Validation of a Post-Traumatic Stress Disorder Questionnaire and Prevalence of PTSD Symptomatology. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17114151"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"113172","DOI":"10.1016\/j.psychres.2020.113172","article-title":"Factors associated with depression, anxiety, and PTSD symptomatology during the COVID-19 pandemic: Clinical implications for U.S. young adult mental health","volume":"290","author":"Liu","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamapsychiatry.2021.0109","article-title":"Posttraumatic Stress Disorder in Patients After Severe COVID-19 Infection","volume":"78","author":"Janiri","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Tu, Y., Zhang, Y., Li, Y., Zhao, Q., Bi, Y., Lu, X., Kong, Y., Wang, L., Lu, Z., and Hu, L. (2021). Post-traumatic stress symptoms in COVID-19 survivors: A self-report and brain imaging follow-up study. Mol. Psychiatry.","DOI":"10.1038\/s41380-021-01223-w"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.1416","article-title":"The role of iron and reactive oxygen species in cell death","volume":"10","author":"Dixon","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.bbagen.2019.06.010","article-title":"Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases","volume":"1863","author":"Nakamura","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tox.2016.07.022","article-title":"Iron overload-induced calcium signals modulate mitochondrial fragmentation in HT-22 hippocampal neuron cells","volume":"365","author":"Lee","year":"2016","journal-title":"Toxicology"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41419-018-0552-7","article-title":"Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK\/MFF\/Drp1 pathway","volume":"9","author":"Zheng","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1039\/C7MT00177K","article-title":"Dietary iron loading negatively affects liver mitochondrial function","volume":"9","author":"Volani","year":"2017","journal-title":"Metallomics"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1074\/jbc.M806235200","article-title":"Mitochondrial DNA damage in iron overload","volume":"284","author":"Gao","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Wu, H., Wang, F., Ta, N., Zhang, T., and Gao, W. (2021). The Multifaceted Regulation of Mitochondria in Ferroptosis. Life, 11.","DOI":"10.3390\/life11030222"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cels.2020.06.008","article-title":"RNA-GPS Predicts SARS-CoV-2 RNA Residency to Host Mitochondria and Nucleolus","volume":"11","author":"Wu","year":"2020","journal-title":"Cell Syst."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41423-020-00603-6","article-title":"Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon response","volume":"18","author":"Cao","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"C258","DOI":"10.1152\/ajpcell.00224.2020","article-title":"Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis","volume":"319","author":"Singh","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41423-020-0514-8","article-title":"SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70","volume":"17","author":"Jiang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1038\/s41467-021-23118-8","article-title":"Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions","volume":"12","author":"Gao","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41598-020-79552-z","article-title":"Host mitochondrial transcriptome response to SARS-CoV-2 in multiple cell models and clinical samples","volume":"11","author":"Miller","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e13001","DOI":"10.15252\/emmm.202013001","article-title":"Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia","volume":"12","author":"Gibellini","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e930886","DOI":"10.12659\/MSM.930886","article-title":"Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce \u2018Brain Fog\u2019 and Results in Behavioral Changes that Favor Viral Survival","volume":"27","author":"Stefano","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e933015","DOI":"10.12659\/MSM.933015","article-title":"Editorial: The Pathogenesis of Long-Term Neuropsychiatric COVID-19 and the Role of Microglia, Mitochondria, and Persistent Neuroinflammation: A Hypothesis","volume":"27","author":"Stefano","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.arcmed.2020.04.019","article-title":"Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection","volume":"51","author":"Mesta","year":"2020","journal-title":"Arch. Med. Res."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2020.06.008","article-title":"Mitochondria and microbiota dysfunction in COVID-19 pathogenesis","volume":"54","author":"Saleh","year":"2020","journal-title":"Mitochondrion"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Valdes-Aguayo, J.J., Garza-Veloz, I., Badillo-Almaraz, J.I., Bernal-Silva, S., Martinez-Vazquez, M.C., Juarez-Alcala, V., Vargas-Rodriguez, J.R., Gaeta-Velasco, M.L., Gonzalez-Fuentes, C., and Avila-Carrasco, L. (2021). Mitochondria and Mitochondrial DNA: Key Elements in the Pathogenesis and Exacerbation of the Inflammatory State Caused by COVID-19. Medicina, 57.","DOI":"10.3390\/medicina57090928"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000510083","article-title":"Ferroptosis Is Regulated by Mitochondria in Neurodegenerative Diseases","volume":"20","author":"Zhou","year":"2020","journal-title":"Neurodegener Dis."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"135627","DOI":"10.1016\/j.neulet.2021.135627","article-title":"Mini-Review: Is iron-mediated cell death (ferroptosis) an identical factor contributing to the pathogenesis of some neurodegenerative diseases?","volume":"745","author":"Viktorinova","year":"2021","journal-title":"Neurosci. Lett."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/jpet.112.192138","article-title":"Mitochondrial dysfunction in neurodegenerative diseases","volume":"342","author":"Johri","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"101107","DOI":"10.1016\/j.redox.2019.101107","article-title":"NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis","volume":"23","author":"Dodson","year":"2019","journal-title":"Redox Biol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1038\/s41467-020-18764-3","article-title":"SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate","volume":"11","author":"Olagnier","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"115241","DOI":"10.1016\/j.taap.2020.115241","article-title":"Fostered Nrf2 expression antagonizes iron overload and glutathione depletion to promote resistance of neuron-like cells to ferroptosis","volume":"407","author":"Liu","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"McCord, J.M., Hybertson, B.M., Cota-Gomez, A., Geraci, K.P., and Gao, B. (2020). Nrf2 Activator PB125((R)) as a Potential Therapeutic Agent against COVID-19. Antioxidants, 9.","DOI":"10.1101\/2020.05.16.099788"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/er.2002-0012","article-title":"Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): Transcriptional coactivator and metabolic regulator","volume":"24","author":"Puigserver","year":"2003","journal-title":"Endocr. Rev."},{"key":"ref_224","first-page":"1452696","article-title":"PGC-1alpha, Inflammation, and Oxidative Stress: An Integrative View in Metabolism","volume":"2020","author":"Millan","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MOL.0b013e328328d0a4","article-title":"PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure","volume":"20","author":"Canto","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fgene.2019.00435","article-title":"Regulation of Mitochondrial Biogenesis as a Way for Active Longevity: Interaction Between the Nrf2 and PGC-1alpha Signaling Pathways","volume":"10","author":"Gureev","year":"2019","journal-title":"Front. Genet."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Millichap, L.E., Damiani, E., Tiano, L., and Hargreaves, I.P. (2021). Targetable Pathways for Alleviating Mitochondrial Dysfunction in Neurodegeneration of Metabolic and Non-Metabolic Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111444"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Bhutta, M.S., Gallo, E.S., and Borenstein, R. (2021). Multifaceted Role of AMPK in Viral Infections. Cells, 10.","DOI":"10.3390\/cells10051118"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijid.2021.02.019","article-title":"The unbalanced p53\/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients","volume":"105","author":"Bordoni","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41366-021-00804-7","article-title":"Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics","volume":"45","author":"Batabyal","year":"2021","journal-title":"Int. J. Obes."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s43141-021-00179-2","article-title":"PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: A review of literature","volume":"19","author":"AbdelMassih","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.bbrc.2015.06.166","article-title":"The PGC-1 coactivators promote an anti-inflammatory environment in skeletal muscle in vivo","volume":"464","author":"Eisele","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Burtscher, J., Millet, G.P., Place, N., Kayser, B., and Zanou, N. (2021). The Muscle-Brain Axis and Neurodegenerative Diseases: The Key Role of Mitochondria in Exercise-Induced Neuroprotection. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126479"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00421-020-04484-5","article-title":"Molecular mechanisms involved in the positive effects of physical activity on coping with COVID-19","volume":"120","author":"Nigro","year":"2020","journal-title":"Eur. J. Appl. Physiol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"110197","DOI":"10.1016\/j.mehy.2020.110197","article-title":"Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy","volume":"143","author":"Heffernan","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"101976","DOI":"10.1016\/j.redox.2021.101976","article-title":"The central role of mitochondrial fitness on antiviral defenses: An advocacy for physical activity during the COVID-19 pandemic","volume":"43","author":"Burtscher","year":"2021","journal-title":"Redox Biol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s42255-020-0237-2","article-title":"A metabolic handbook for the COVID-19 pandemic","volume":"2","author":"Ayres","year":"2020","journal-title":"Nat. Metab."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"113309","DOI":"10.1016\/j.expneurol.2020.113309","article-title":"Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases","volume":"329","author":"Simmons","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13073-021-00863-5","article-title":"Microglial PGC-1alpha protects against ischemic brain injury by suppressing neuroinflammation","volume":"13","author":"Han","year":"2021","journal-title":"Genome Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12640-020-00292-z","article-title":"A New Perspective on Ameliorating Depression-Like Behaviors: Suppressing Neuroinflammation by Upregulating PGC-1alpha","volume":"39","author":"Fu","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.3389\/fimmu.2019.02650","article-title":"Isovitexin-Mediated Regulation of Microglial Polarization in Lipopolysaccharide-Induced Neuroinflammation via Activation of the CaMKKbeta\/AMPK-PGC-1alpha Signaling Axis","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.7150\/thno.37119","article-title":"Upregulation of neuronal PGC-1alpha ameliorates cognitive impairment induced by chronic cerebral hypoperfusion","volume":"10","author":"Han","year":"2020","journal-title":"Theranostics"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"105640","DOI":"10.1016\/j.phrs.2021.105640","article-title":"Medioresinol as a novel PGC-1alpha activator prevents pyroptosis of endothelial cells in ischemic stroke through PPARalpha-GOT1 axis","volume":"169","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12974-021-02250-8","article-title":"NAD(+) improves cognitive function and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS production in chronic cerebral hypoperfusion models through Sirt1\/PGC-1alpha pathway","volume":"18","author":"Zhao","year":"2021","journal-title":"J. Neuroinflam."},{"key":"ref_245","first-page":"3542","article-title":"Protective effects of melatonin on mitochondrial biogenesis and mitochondrial structure and function in the HEK293-APPswe cell model of Alzheimer\u2019s disease","volume":"23","author":"Wang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"117583","DOI":"10.1016\/j.lfs.2020.117583","article-title":"COVID-19: Melatonin as a potential adjuvant treatment","volume":"250","author":"Zhang","year":"2020","journal-title":"Life Sci."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"173329","DOI":"10.1016\/j.ejphar.2020.173329","article-title":"Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19","volume":"882","author":"Othman","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.2147\/JIR.S323356","article-title":"Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation","volume":"14","author":"Castle","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jmv.27312","article-title":"Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial","volume":"94","author":"Mousavi","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"4946711","DOI":"10.1155\/2021\/4946711","article-title":"Targeting Mitochondrial Biogenesis with Polyphenol Compounds","volume":"2021","author":"Chodari","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Wood Dos Santos, T., Cristina Pereira, Q., Teixeira, L., Gambero, A., Villena, J.A., and Lima Ribeiro, M. (2018). Effects of Polyphenols on Thermogenesis and Mitochondrial Biogenesis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092757"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/1750-3841.14723","article-title":"Promotion of Mitochondrial Biogenesis via Activation of AMPK-PGC1a Signaling Pathway by Ginger (Zingiber officinale Roscoe) Extract, and Its Major Active Component 6-Gingerol","volume":"84","author":"Deng","year":"2019","journal-title":"J. Food Sci."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Rahman, M.A., Rahman, M.H., Biswas, P., Hossain, M.S., Islam, R., Hannan, M.A., Uddin, M.J., and Rhim, H. (2020). Potential Therapeutic Role of Phytochemicals to Mitigate Mitochondrial Dysfunctions in Alzheimer\u2019s Disease. Antioxidants, 10.","DOI":"10.20944\/preprints202012.0059.v1"},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Stromsnes, K., Lagzdina, R., Olaso-Gonzalez, G., Gimeno-Mallench, L., and Gambini, J. (2021). Pharmacological Properties of Polyphenols: Bioavailability, Mechanisms of Action, and Biological Effects in In Vitro Studies, Animal Models, and Humans. Biomedicines, 9.","DOI":"10.3390\/biomedicines9081074"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"107422","DOI":"10.1016\/j.intimp.2021.107422","article-title":"Curcumin protects against cognitive impairments in a rat model of chronic cerebral hypoperfusion combined with diabetes mellitus by suppressing neuroinflammation, apoptosis, and pyroptosis","volume":"93","author":"Zheng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40121-021-00400-2","article-title":"Computational and Experimental Studies Reveal That Thymoquinone Blocks the Entry of Coronaviruses into In Vitro Cells","volume":"10","author":"Xu","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"106899","DOI":"10.1016\/j.vph.2021.106899","article-title":"The potential role of thymoquinone in preventing the cardiovascular complications of COVID-19","volume":"141","author":"Ahmad","year":"2021","journal-title":"Vasc. Pharmacol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2147\/DDDT.S308863","article-title":"Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure","volume":"15","author":"Badary","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Muchtaridi, M., Fauzi, M., Khairul Ikram, N.K., Mohd Gazzali, A., and Wahab, H.A. (2020). Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. Molecules, 25.","DOI":"10.3390\/molecules25173980"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1080\/07391102.2020.1778537","article-title":"Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: Using structure-based drug discovery approach","volume":"39","author":"Shafreen","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"111356","DOI":"10.1016\/j.biopha.2021.111356","article-title":"Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies","volume":"137","author":"Kumar","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Huang","year":"2020","journal-title":"Nat. Med."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/ijms.46614","article-title":"Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): A case-control study","volume":"17","author":"Pan","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1038\/s41467-021-25191-5","article-title":"The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients","volume":"12","author":"Perreau","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s13365-018-0695-4","article-title":"Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer\u2019s disease","volume":"25","author":"Pulliam","year":"2019","journal-title":"J. Neurovirol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/QAD.0000000000002272","article-title":"Profile of neuronal exosomes in HIV cognitive impairment exposes sex differences","volume":"33","author":"Sun","year":"2019","journal-title":"AIDS"},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Frontera, J.A., Boutajangout, A., Masurkar, A.V., Betensky, R.A., Ge, Y., Vedvyas, A., Debure, L., Moreira, A., Lewis, A., and Huang, J. (2022). Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer\u2019s dementia. Alzheimers Dement.","DOI":"10.1101\/2021.09.01.21262985"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13195-021-00805-8","article-title":"Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer\u2019s disease pathology and clinical disease progression","volume":"13","author":"Clark","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","article-title":"Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design","volume":"23","author":"Malone","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_272","first-page":"298","article-title":"Mitochondrial Organelle Transplantation Is a Potential Therapeutic for Mitochondria Dysfunction in Severe Acute Respiratory Syndrome (SARS) Coronavirus Diseases","volume":"11","author":"Baucom","year":"2021","journal-title":"Adv. Infect. Dis."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"695362","DOI":"10.3389\/fcell.2021.695362","article-title":"Targeted Mitochondrial Therapy with Over-Expressed MAVS Protein from Mesenchymal Stem Cells: A New Therapeutic Approach for COVID-19","volume":"9","author":"Babajani","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Yamada, Y., Ito, M., Arai, M., Hibino, M., Tsujioka, T., and Harashima, H. (2020). Challenges in Promoting Mitochondrial Transplantation Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176365"},{"key":"ref_275","first-page":"636","article-title":"Mitochondrial Transplantation: A Critical Analysis","volume":"85","author":"Chernyak","year":"2020","journal-title":"Biochemistry"},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"Park, A., Oh, M., Lee, S.J., Oh, K.J., Lee, E.W., Lee, S.C., Bae, K.H., Han, B.S., and Kim, W.K. (2021). Mitochondrial Transplantation as a Novel Therapeutic Strategy for Mitochondrial Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094793"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"752227","DOI":"10.3389\/fimmu.2021.752227","article-title":"Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics","volume":"12","author":"Kumar","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"658519","DOI":"10.3389\/fimmu.2021.658519","article-title":"Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2\/COVID-19 Pandemic Management: A Review on the Recent Update","volume":"12","author":"Anand","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"729559","DOI":"10.3389\/fpubh.2021.729559","article-title":"Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/bmjspcare-2020-002554","article-title":"Evaluation of current medical approaches for COVID-19: A systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_281","first-page":"CD015017","article-title":"Ivermectin for preventing and treating COVID-19","volume":"7","author":"Popp","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_282","first-page":"CD015025","article-title":"Antibiotics for the treatment of COVID-19","volume":"10","author":"Popp","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_283","first-page":"CD014962","article-title":"Remdesivir for the treatment of COVID-19","volume":"8","author":"Ansems","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_284","first-page":"CD014963","article-title":"Systemic corticosteroids for the treatment of COVID-19","volume":"8","author":"Wagner","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","article-title":"Azithromycin in the treatment of COVID-19: A review","volume":"19","author":"Ferrandez","year":"2021","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"111008","DOI":"10.1016\/j.biopha.2020.111008","article-title":"Prevention and treatment of COVID-19: Focus on interferons, chloroquine\/hydroxychloroquine, azithromycin, and vaccine","volume":"133","author":"Bakadia","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_287","doi-asserted-by":"crossref","unstructured":"Juul, S., Nielsen, E.E., Feinberg, J., Siddiqui, F., Jorgensen, C.K., Barot, E., Holgersson, J., Nielsen, N., Bentzer, P., and Veroniki, A.A. (2021). Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248132"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/12\/2\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:11:19Z","timestamp":1760134279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/12\/2\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":287,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["brainsci12020190"],"URL":"https:\/\/doi.org\/10.3390\/brainsci12020190","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]}}}